I.R MED LTD

Non-invasive biomarker analysis of blood & tissue at the point-of-care, based on IR-MED’s patented spectrographic technology & AI-enhanced platform, enables handheld early detection of Pressure Injuries and Diabetic Foot Ulcers (DFU). Approved by FDA

IR MED is a developer of a noninvasive artificial intelligence-driven spectrographic analysis technology platform to address significant healthcare needs.

Anesthesiologists, gastroenterologists, plastic surgeons, dental doctors, who use Propofol sedation in out patient clinics, in office procedures and in the OR arena.

Ran Ziskind - CEO

Ronnie Klein - CTO & Co-Founder

Sharon Levkoviz - CFO